Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials

Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 (PARP-1) causing resistance to radiation therapy. Thus, PARP-1 represents an important target in multiple cancer types...

Descripción completa

Detalles Bibliográficos
Autores principales: NAMBIAR, DHANYA K., MISHRA, DEEPALI, SINGH, RANA P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tech Science Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319588/
https://www.ncbi.nlm.nih.gov/pubmed/37415740
http://dx.doi.org/10.32604/or.2023.028310
_version_ 1785068268501860352
author NAMBIAR, DHANYA K.
MISHRA, DEEPALI
SINGH, RANA P.
author_facet NAMBIAR, DHANYA K.
MISHRA, DEEPALI
SINGH, RANA P.
author_sort NAMBIAR, DHANYA K.
collection PubMed
description Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 (PARP-1) causing resistance to radiation therapy. Thus, PARP-1 represents an important target in multiple cancer types, including prostate cancer. PARP is a nuclear enzyme essential for single-strand DNA breaks repair. Inhibiting PARP-1 is lethal in a wide range of cancer cells that lack the homologous recombination repair (HR) pathway. This article provides a concise and simplified overview of the development of PARP inhibitors in the laboratory and their clinical applications. We focused on the use of PARP inhibitors in various cancers, including prostate cancer. We also discussed some of the underlying principles and challenges that may affect the clinical efficacy of PARP inhibitors.
format Online
Article
Text
id pubmed-10319588
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Tech Science Press
record_format MEDLINE/PubMed
spelling pubmed-103195882023-07-06 Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials NAMBIAR, DHANYA K. MISHRA, DEEPALI SINGH, RANA P. Oncol Res Review Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 (PARP-1) causing resistance to radiation therapy. Thus, PARP-1 represents an important target in multiple cancer types, including prostate cancer. PARP is a nuclear enzyme essential for single-strand DNA breaks repair. Inhibiting PARP-1 is lethal in a wide range of cancer cells that lack the homologous recombination repair (HR) pathway. This article provides a concise and simplified overview of the development of PARP inhibitors in the laboratory and their clinical applications. We focused on the use of PARP inhibitors in various cancers, including prostate cancer. We also discussed some of the underlying principles and challenges that may affect the clinical efficacy of PARP inhibitors. Tech Science Press 2023-06-27 /pmc/articles/PMC10319588/ /pubmed/37415740 http://dx.doi.org/10.32604/or.2023.028310 Text en © 2023 Nambiar, Mishra and Singh https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
NAMBIAR, DHANYA K.
MISHRA, DEEPALI
SINGH, RANA P.
Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials
title Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials
title_full Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials
title_fullStr Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials
title_full_unstemmed Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials
title_short Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials
title_sort targeting dna repair for cancer treatment: lessons from parp inhibitor trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319588/
https://www.ncbi.nlm.nih.gov/pubmed/37415740
http://dx.doi.org/10.32604/or.2023.028310
work_keys_str_mv AT nambiardhanyak targetingdnarepairforcancertreatmentlessonsfromparpinhibitortrials
AT mishradeepali targetingdnarepairforcancertreatmentlessonsfromparpinhibitortrials
AT singhranap targetingdnarepairforcancertreatmentlessonsfromparpinhibitortrials